International innovative lung cancer drug completes its first clinical use in China

Hainan Province and Drug Administration, Hainan health committee meeting, Haikou Customs have jointly issued a circular on "further improve the regulatory service support Boao Music City international medical tourism first area of the development of several high-quality measures", "a number of measures" aimed at Further optimize the business environment of the Hainan Boao Lecheng International Medical Tourism Pioneer Zone, simplify the approval process for clinically urgently needed imported drugs and medical devices, optimize the approval model, improve the effectiveness of supervision services, and facilitate the timely use of clinically needed imported drugs and medical devices, and help Hainan Lecheng to move ahead District high-quality development
.

In February 2013, the State Council approved the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot Zone to pilot the development of international medical tourism related industries such as licensed medical care, tumor prevention, health management, nursing and rehabilitation, medical beauty and anti-aging, aiming to focus on international and domestic high-end medical tourism Services and international cutting-edge medical science and technology achievements, creating an international medical technology service industry cluster
.

Lung cancer is a malignant tumor with high incidence and high mortality in the world.
The incidence and fatality rate of lung cancer in China ranks first among malignant tumors.
For a long time, due to the lack of effective treatment methods, the 5-year survival rate of lung cancer patients in China is only about 16%
.

In May 2021, the US FDA approved the listing of LUMAKRAS (Sotorasib).
LUMAKRAS became the world's first approved anti-tumor drug targeting KRAS mutations.
LUMAKRAS targets locally advanced or metastatic KRAS G12C mutants that have received at least one systemic treatment in the past.
Adult patients with non-small cell lung cancer
.

With the support of Hainan Lecheng Administration Bureau, Boao Super Hospital, Hainan Provincial Tumor Hospital and BeiGene, etc.
, after a rigorous evaluation of the patient’s condition by the team of Professor Wang Meiqing, Department of Oncology, Hainan Provincial Tumor Hospital, on September 14, 2021, one KRAS G12C mutation non-small cell lung cancer patients in the Boao Super Hospital in the Lecheng pilot area of ​​Hainan successfully took the world's first innovative drug LUMAKRAS for the treatment of KRAS G12C mutations in non-small cell lung cancer
.

Professor Wang Meiqing introduced that the current prognosis of advanced lung cancer patients with KRAS G12C mutations is poor.
The main treatment options are chemotherapy and immunotherapy.
Previously, once chemotherapy or immunotherapy failed in KRAS G12C patients, there were basically no targeted treatment options available in the advanced stage
.